生物活性 | |||
---|---|---|---|
描述 | NIBR-0213 emerges as a potent, orally active antagonist of the S1P1 receptor, demonstrating efficacy in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. NIBR-0213 exhibits remarkable potency and selectivity towards S1P1 across species, with IC50 values of 2.0 nM and 2.3 nM in human and rat S1P1 receptors, respectively, in GTPγ35S assays[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.15mL 0.43mL 0.22mL |
10.75mL 2.15mL 1.08mL |
21.51mL 4.30mL 2.15mL |
参考文献 |
---|